The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Divestment is part of BASF’s strategic portfolio optimization
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Subscribe To Our Newsletter & Stay Updated
